ing an additional unintended pregnancy with ulipristal acetate as compared to levonorgestrel is estimated to be 418€ . Ulipristal acetate is most cost-effective in the subgroup of intake within 24 hours, where it is more efficacious at a lower cost compared to levonorgestrel. ConClusions: Ulipristal acetate is a cost-effective alternative to levonorgestrel, given that the cost of avoiding an additional pregnancy with ulipristal acetate is less than the average cost of said pregnancies. Therefore, French minors should have free access to ulipristal acetate directly in a pharmacy. Ulipristal acetate should be used rapidly after unprotected intercourse (within 24hours) to benefit from its cost-saving potential compared to levonorgestrel use.

No abstract

peanut 5 (21%), egg 3 (13%), fish 1 (4%) and fruits 1 (4%). Peanut could be reintroduced to all children after CRD, egg and milk after specific IgE IVD. Prior to the introduction of food a secondary care specialist food provocation was performed to confirm the IVD result. ConClusions: CRD ISAC was beneficial in 54% of the cases and in 21% of the cases it was critical for decision making. The aim of the study was reached as avoidance diets decreased by 63%. The results indicate, even with low patient recruitment, it is likely that introducing ISAC IVD to traditional diagnostic algorithm can be considered cost-effective, with an average cost per avoided unnecessary diet for 480 EURs per child. To confirm the findings a larger study will be executed.

Objectives: To estimate long-term clinical outcomes of using rilpivirine/tenofovir/emtricitabine (single tablet regimen) in treatment of naïve patients with HIV-1 RNA< 100 000 copies/ml in the Russian Federation. MethOds: The mathematical model was developed in Microsoft Office 2013. The time horizon was 5 years. The model included two submodels: Markov's model and tree-decision model. The following outcome measures were used in present study: Number of deaths, Years of life lost, Number of hospitalizations. All calculations were based on results of published clinical, epidemiological and social researches. Data for patients with HIV was obtained from prior epidemiological studies that had been provided in the Russian Federation. Results: The number of deaths on rilpivirine/tenofovir/emtricitabine scheme (single tablet regimen) was 12% and 15% less, the number of YLL was 9% and 12% less and Number of hospitalizations was 19,91% and 19,88% less than on the schemes efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir + tenofovir/ emtricitabin (multi-pill regimen), respectively. cOnclusiOns: Results obtained with present model showed that treatment naïve patients with HIV-1 RNA< 100 000 copies/ml using rilpivirine/tenofovir/emtricitabine scheme (single tablet regimen) can be associated with better long-term outcomes compared to alternative multi-pill schemes.

A875substantially higher objective response rates favouring patients receiving nivolumab (25.1% vs 5.4%; odds ratio: 5.98, P< 0.001) was observed in this trial. The aim of this analysis was to compare the monthly cost per responder with nivolumab versus everolimus in the Brazilian private healthcare system perspective. Methods: This analysis was based on investigator-based patient-level data from a randomized phase III trial. ORR was defined as the proportion of patients who achieved a partial or complete response. Costs were calculated based on drug, administration, and managing of grade 1-4 treatment related adverse events (TRAEs) reported on Checkmate 025. Drug costs for nivolumab and everolimus were obtained from the official Brazilian price list (Feb/2017) by CMED. The management of TRAEs was obtained through a Delphi panel, followed by microcosting of resources obtained from public sources (Kairos and Simpro Magazine n105/2016 for drugs and materials, CBHPM 2016 for medical appointments and procedures, and UNIDAS National Research 2015 for hospitalizations). Monthly cost per objective response was calculated by dividing the average monthly cost per patient by ORR. Results: Median duration of treatment was 5.